A new generation of therapeutic modalities

Jun 8, 2020 | Biopharma, Blogs, Pharma | 0 comments

There are over 7,000 genetic diseases that could potentially be cured using gene therapy. Rare metabolic diseases, autoimmune disorders, cardiovascular disease and cancers are some of the top disease classes that can be addressed with gene therapies. With over 1,000 clinical trials involving gene therapies or oligonucleotides currently in various stages, and 11 gene therapy drugs already on the market, it is clear the potential benefit to human health is profound.

This new generation of therapeutic modalities presents unprecedented technological challenges in bringing therapies to patients. These challenges have affected both the speed and ultimate cost of bringing new therapies to market, with many gene therapeutics now categorized as some of the most expensive medications currently in existence. Ultimately, there is a lack of sufficient tools as we seek faster and more accurate methods for characterizing these new classes of drugs.

Although faced with many unique challenges and still at its very early stages, the global gene therapy market is growing rapidly. As of 2019, the size of this market is estimated to be more than $1 billion, and it is expected to expand at a compound annual growth rate (CAGR) of 32%. This growth is primarily driven by an increase in the number of clinical trials, the amount of government and private funding and the number of partnerships between small biotech and large pharmaceutical companies.

This type of growth brings many opportunities, and to take advantage of them, it is crucial that you are prepared with solutions to the challenges ahead. To help you succeed, we invite you to download a copy of the gene therapy and oligonucleotide compendium. This compendium was created with you in mind, and it aims to provide you with precision analytics that will help bring your therapies to market faster.

The compendium includes:

  • An overview of current trends and the market landscape
  • Workflows and approaches to purity testing, sizing sequencing and expression analysis
  • Strategies for better understanding the biological impact of genetic mutations and specific gene editing events
  • Discover how to accelerate your gene therapy and oligonucleotide development by getting the right answers the first time through precise analytics you can trust.

Download now >

Telling the PFAS story with pine needles

As an ever-expanding group of chemicals, per- and polyfluoroalkyl substances (PFAS) require novel techniques to monitor their current and historical presence in the environment. Concerns over exposure to PFAS chemicals continue to grow, with some having known toxic characteristics and the potential effects of others remaining unknown.1 In addition, while PFAS are one of the most persistent synthetic chemicals to date, most of them hardly degrade in the environment.2 So, how long do traces of PFAS last in our environment? Two tools used to help answer this question are active samplers and passive samplers.

Back to the new basics: Part 3 | LC vs. LC-MS and what it means for your lab

In this final installment of our “Back to the new basics” series, we take one more look at analytical techniques and best practices in the lab, and opportunities to improve efficiency. Here, we explore the basic principles of high-performance liquid chromatography (LC) and liquid chromatography mass spectrometry (LC-MS), and how these techniques can affect a lab’s efficiency and productivity.

Meat vs plant based. What is the best option?

As we become more conscious about the planet, healthier lifestyles and our duty to protect the environment, attitudes and behaviours are shifting when it comes to food consumption.

Posted by

0 Comments

Submit a Comment